Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 30, 2019

Primary Completion Date

May 30, 2021

Study Completion Date

October 31, 2021

Conditions
Urinary IncontinenceUrgency Urinary
Interventions
DRUG

Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine

Study participants will be evaluated for urgency urinary incontinence and will be offered treatment with a standard of care anticholinergic medication for 6 weeks. All study participants will fill out the UDI-6 and two day bladder diary at baseline before starting anticholinergic medication treatment. Participants will then provide a urine sample and blood draw to be assessed for urinary microbiome and inflammation. Anticholinergic medication will be taken daily for 6 weeks and the same procedures (UDI-6 questionnaire, bladder diary, urine sample except the blood draw for assessment) will be performed at the 6-week time period.

Trial Locations (1)

02115

Brigham & Women's Hospital, Boston

All Listed Sponsors
collaborator

Medical University of Silesia

OTHER

lead

Brigham and Women's Hospital

OTHER

NCT04090190 - Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics | Biotech Hunter | Biotech Hunter